2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial.

Autor: Lehtonen M; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.; Katriina Hospital, Vantaa, Finland., Sormunen J; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.; Docrates Cancer Center, Helsinki, Finland., Luukkaala T; Research, Development and Innovation Center, Tampere University Hospital and Health Sciences, Faculty of Social Sciences, Tampere University, Tampere, Finland., Marttila T; Seinäjoki Central Hospital, Seinäjoki, Finland., McDermott R; St Vincent's University Hospital and Cancer Trials, Dublin, Ireland., Joensuu T; Docrates Cancer Center, Helsinki, Finland., Lehtinen I; Faculty of Information Technology and Communication Sciences, Tampere University, Tampere, Finland., Ginman C; Karlstad Central Hospital, Karlstad, Sweden., Kellokumpu-Lehtinen PL; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.; Tampere University Hospital Cancer Center, Tampere, Finland.
Jazyk: angličtina
Zdroj: Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2022 Aug; Vol. 61 (8), pp. 963-971. Date of Electronic Publication: 2022 Jul 18.
DOI: 10.1080/0284186X.2022.2098680
Abstrakt: Introduction: Treatment with 2-weekly docetaxel 50 mg/m 2 was shown to improve overall survival and was better tolerated than the standard 75 mg/m 2 3-weekly regimen in men with metastatic castration-resistant prostate cancer (mCRPC) in the original randomised PROSTY trial. The aim of this study was to investigate, whether quality of life (QoL) effects would differ between the 2-weekly docetaxel 50 mg/m 2 regimen from the standard 3-weekly 75 mg/m 2 treatment.
Materials and Methods: QoL data were collected with the Functional Assessment of Cancer Therapy - Prostate (FACT-P) and Functional Assessment of Cancer Therapy Advanced Prostate Symptom Index - 8 Item version (FAPSI-8). Pain was measured using the Visual Analogue Scale (VAS). A total of 743 forms from 163 patients were analysed in Arm A (2-weekly docetaxel), and 704 forms from 173 patients were analysed in Arm B (3-weekly docetaxel). The data were analysed using both the Wilcoxon signed rank test (with Holm-Bonferroni adjustment) and Mann-Whitney U models.
Results: No major differences were found in total QoL. Total QoL was higher at month 8 in Arm B ( p  = .020), but this was reversed in the following month ( p  = .043), and no statistically significant differences were found during other months. Compared to Arm A, participants in Arm B had longer-lasting deterioration in FAPSI-8 scores and emotional well-being subdomain at the beginning of treatment ( p  < .05). Various one-month differences were found in FACT-P subdomains (except for functional well-being), and these favoured participants in Arm A, except for the prostate-cancer subdomain. There were no differences in pain.
Conclusion: Based on our results, 2-weekly docetaxel was not inferior to 3-weekly docetaxel in terms of total health-related QoL and seemed to be superior at least in terms of the FAPSI-8 and emotional well-being subdomain in the first three to four months of treatment. More research on the topic is suggested to confirm the results.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje